Vivimed exports its first shipment, Famotidine tablets, to Canada

Vivimed Labs, a niche speciality chemicals and pharma company, announced the export of its first shipment to Canada –  Famotidine tablets 40 mg and 20 mg manufactured in its Vivimed Hyderabad site which is approved by Health CANADA. Famotidine tablets are histamine H2 receptor antagonists used for:

• relief of heartburn, indigestion, upset stomach, sour stomach due to excess stomach acid, hyperacidity and/or acid indigestion and

• prevention of the symptoms of excess stomach acid brought on by consuming food and/or beverages which may cause symptoms

Commenting on the development, Ramesh Krishnamurthy, CEO of Vivimed Labs said, “Successful launch of Famotidine is a demonstration of Vivimed’s CDMO capability to prestigious Canada market in collaboration with a highly respected strategic partner. This sets the stage for exciting new range of CDMO products. In the next six months, Vivimed shall continue to leverage end to end capabilities to expand its CDMO foot print.”